行 业 及 产 业 医药生物 行 业 研 究 / 行 业 点 评 证 券 研 究 报 告 《本周申万医药生物指数下跌 0.8%，关注 基药目录发布——医药行业周报 （2026/02/09-2026/02/20）》 2026/02/23 《本周申万医药生物指数上涨 0.14%，关 注中药高质量发展方案——医药行业周报 （2026/02/02-2026/02/06）》 2026/02/09 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 陈田甜 A0230524080013 chentt@swsresearch.com 联系人 陈田甜 A0230524080013 chentt@swsresearch.com 2026 年 03 月 02 日 本 周 申 万 医 药 生 物 指 数 上 涨 0.5%，关注大宗原料药价格上涨 看好 —— 医药行业周报（2026/02/23-2026/02/27） 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 相关研究 ⚫ 市场表现：本周申万医药生物指数上涨 0.5%，同期 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, emphasizing the potential for investment in bottom assets within the industry [5]. Core Insights - The report highlights the ongoing opportunities in the pharmaceutical sector, particularly in areas such as AI in medicine and innovative drug developments, while noting the recent market performance where the pharmaceutical sector outperformed the broader market [11][26]. - It emphasizes the importance of monitoring key milestones and data updates from major conferences in 2026, such as AACR and ASCO, which could significantly impact investment decisions [11]. Summary by Sections Market Performance - The pharmaceutical sector has shown a return of 3.28% since the beginning of 2026, outperforming the Shanghai Composite Index by 2.99 percentage points [26]. - Recent weekly performance indicates a slight increase in the pharmaceutical sector by 0.14%, while the broader market declined by 1.33% [11][26]. Investment Opportunities - The report identifies several key areas for investment, including: - IO plus strategies involving VEGF dual antibodies, which are gaining traction in clinical trials [12]. - ADC (Antibody-Drug Conjugates) with a focus on large indications and new indications that could enhance overseas mapping [14]. - The development of new RAS inhibitors and their potential in treating various cancers, highlighting companies like 加科思 and 劲方生物 [15]. - The commercial potential of CDK4/6 inhibitors in HR+ breast cancer, particularly as patents expire [16]. Key Companies and Recommendations - The report recommends several companies for investment, including: - 药明生物, 泰格医药, 先声药业, 康弘药业, 普洛药业, 美好医疗, 迪安诊断, 和铂医药-B, 药石科技, and 天宇股份, all of which are expected to perform well in the current market environment [8][19]. - It notes that the pharmaceutical sector's current valuation is 22.8 times PE based on 2026 earnings forecasts, indicating a premium over the broader A-share market [30]. Clinical Developments - The report discusses various clinical trials and their implications, such as: - The anticipated data readouts for several ADCs and dual antibodies in 2026, which could significantly influence market dynamics [17][20]. - The ongoing advancements in small nucleic acids and their expected commercialization, which could lead to substantial market growth [19][23]. Regulatory Environment - The report highlights the regulatory landscape, noting that the National Medical Insurance Administration will intensify oversight in 2026, which may impact pharmaceutical companies [22]. Overall Sector Outlook - The report maintains a positive outlook on the pharmaceutical sector, suggesting that despite recent market fluctuations, there are significant opportunities for growth and investment, particularly in innovative therapies and technologies [11][19].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector is experiencing a rebound in bottom assets, particularly in traditional Chinese medicine, medical services, and pharmacies, driven by market rotation and price increase expectations in raw materials [7][11] - The report emphasizes the importance of focusing on bottom assets that are expected to see turning points and well-adjusted innovative drug sectors, with a positive outlook on growth directions representing the future of the pharmaceutical industry [11] - Key themes include continuous attention to pharmaceutical and medical AI+, as well as significant data updates expected from major conferences in 2026 [11] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 3.28% compared to the Shanghai Composite's 0.29% since the beginning of 2026 [26] - The report notes that the pharmaceutical sector's valuation is currently at 22.8 times PE, with a premium of 11.7% over the overall A-share market [30] Key Company Performance - Recommended stocks for February include WuXi Biologics, Tigermed, and others, with a focus on companies that have shown significant pipeline progress or business development expectations [8][36] - The report highlights the performance of companies like Guangsheng Tang and Nuo Cheng Jian Hua, which have made notable advancements in their core pipelines [36] Industry Trends - The report discusses the trend of combining IO plus therapies and the development of new targets in the dual antibody space, indicating a growing trend in clinical applications [12][14] - Attention is drawn to the ADC (Antibody-Drug Conjugate) sector, particularly large indication FIC (First-in-Class) products and the potential for new indications to enhance overseas mapping [14][17] - The report also highlights the evolving landscape in blood cancers, with new therapies showing promise in previously underserved areas [20]

Market Overview - The Hang Seng Index closed down by 0.29% at 26,487.51 points, while the Hang Seng Tech Index fell by 1.16% to 5,683.44 points [1][2] - The total trading volume for the Hang Seng Index was 2,378 billion, and for the Hang Seng Tech Index, it was 663 billion [2] Sector Performance Technology Sector - Major tech stocks led the decline, with SMIC and Sunny Optical falling over 3%, and Xiaomi, BYD Electronics, SenseTime, and Hua Hong Semiconductor also experiencing losses [2] Biotech Sector - The biotech sector continued its downward trend, with major companies like Hengrui Medicine and WuXi AppTec dropping over 4% [3] New Consumption Sector - The new consumption sector showed strength, with Pop Mart and Heytea rising by 9%, and Blukoo increasing by nearly 4% [5] Gold Sector - The gold sector saw significant gains, with the International Gold Group rising over 7%, and Zijin Mining and King Precious Metals increasing by over 5% [7][8]

Market Performance - The Shanghai Composite Index fell by 0.26% to 4101.91 points, while the Shenzhen Component decreased by 0.18% and the ChiNext Index dropped by 0.2%[1] - The Hong Kong Hang Seng Index closed down 0.29% at 26844.96 points, with the Hang Seng Tech Index down 0.11% and the Hang Seng China Enterprises Index down 0.50%[1] - The total market turnover in Hong Kong was 2550.786 million HKD[1] Economic and Policy Developments - President Trump announced a 10% tariff on eight European countries starting February 1, increasing to 25% in June unless a Greenland acquisition agreement is reached[12] - The EU is reportedly discussing retaliatory tariffs against the U.S. in response to these measures[12] - Market speculation has shifted towards Kevin Walsh as a potential new Federal Reserve Chair, reducing expectations for interest rate cuts this year[12] Financial Data Insights - The U.S. Dow Jones Industrial Average fell by 0.17% to 49359.33 points, while the S&P 500 and Nasdaq both decreased by 0.06%[1] - Bloomberg forecasts that China's Q4 GDP growth may slow to 4.5%, down from 4.8% in Q3, marking a three-year low[12] - The one-year Loan Prime Rate (LPR) is expected to remain stable at 3.00%, with the five-year LPR also unchanged at 3.50%[12]

12月22日，恒生指数高开0.41%，恒生科技指数涨0.61%。 多只生物医药股走低，歌礼制药-B、金斯瑞生物科技、东阳光药、和铂医药-B均跌超3%。 | 名称 | 现价 | 涨跌幅 ◆ | | --- | --- | --- | | 华茌生物-B | 33.800 | -11.52% | | 2396.HK | | | | 歌礼制药-B | 12.500 | -3.85% | | 1672.HK | | | | 金斯瑞生物科技 | 12.750 | -3.56% | | 1548.HK | | | | 东阳光药 | 43.020 | -3.46% | | 6887.HK | | | | 和铂医药-B | 12.880 | -3.45% | | 2142.HK | | | | 加科思-B | 8.800 | -2.87% | | 1167.HK | | | | 乐普生物-B | 5.340 | -1.66% | | 2157.HK | | | | MIRXES-B | 46.600 | -1.10% | | 2629.HK | | | | 三爱健康集团 | 0.490 | -1.01% | | 1889.HK ...

Group 1 - The actual controller of Weining Health, Zhou Wei, was sentenced to one and a half years in prison and fined 200,000 yuan, while the company was fined 800,000 yuan, with both parties deciding to appeal the verdict [1] - Weining Health claims that this incident will not have a significant adverse impact on its operations, but the involvement of its actual controller raises concerns about corporate governance and reputation [1] Group 2 - Northeast Pharmaceutical was ordered to pay 16.45 million yuan in damages due to a contract dispute, with the court rejecting other claims from the plaintiff [2] - This ruling represents a substantial financial loss for Northeast Pharmaceutical and highlights potential weaknesses in its internal controls and contract management [2] Group 3 - Novo Nordisk's semaglutide sales reached $25.462 billion in the first three quarters, a 24% increase year-on-year, maintaining a slight lead over Eli Lilly's tirzepatide, which generated $24.837 billion in sales [3] - The competition between semaglutide and tirzepatide reflects the significant market demand and innovation in the metabolic disease sector, indicating ongoing technological advancements and market expansion [3] Group 4 - HAPO Pharma's subsidiary has entered into an evaluation and licensing agreement with Umoja Biopharma to combine their platforms for the development of CAR-T cell products [4] - This partnership not only validates the technological value of HAPO Pharma's core platforms but also opens up a path for milestone payments, alleviating financial pressure and showcasing the commercialization potential of cutting-edge technologies [4]

2025年以来，港股市场的创新药板块批量式诞生了一大批牛股，同时还有源源不断的中国创新药企奔赴 港股市场。在这一背景下，国际资本也在持续加码中国创新药。 对此，不少创投机构人士指出，近年来中国创新药发展迅速，获得了众多国际医药巨头的青睐，签署了 一大批共同开拓全球市场的合作协议，产业繁荣也将带动资本繁荣，未来也势必会被更多国际资本青 睐。不过，也有行业人士指出，中国创新药未来不仅需要补齐出海短板，还需要更多原创。 国际资本多渠道加码 2025年以来，国际资本正通过签署BD（Business Development，业务发展）协议、参与基石投资、二级 市场增持等多种方式持续加码港股市场上的中国创新药资产。 此外，一些国际资本也在二级市场上持续买入，以最为活跃的新加坡政府投资公司（GIC）为例，其近 期在二级市场上连续增持了和铂医药-B和基石药业-B，显示出国际资本对中国创新药产业的看好。 对此，一家创投机构人士黄鹏（化名）告诉证券时报记者："国内的创新药确实发展得很快，中国的创 新资产占全球的比例也越来越高，未来肯定会有更多的国际资本青睐，行业会继续蓬勃发展。" 多因素推动创新药牛市 在国际资本不断加码以及众多 ...

Group 1 - The core point of the news is that the Hong Kong innovative pharmaceutical sector experienced a significant decline, with major stocks dropping over 10% due to reports of potential restrictions on Chinese drugs by the Trump administration [1][2][5] - Key stocks affected include Basilea Pharmaceutica-B, Hansoh Pharmaceutical, and Kelun-B, all of which opened lower by 15%, 14.98%, and 12.97% respectively [1][2] - The decline in the innovative pharmaceutical sector also impacted related ETFs, with several Hong Kong Stock Connect innovative drug ETFs dropping over 6% in early trading [2] Group 2 - The report from The New York Times indicated that the Trump administration is drafting an executive order to impose strict limitations on Chinese pharmaceuticals, particularly experimental drugs, which contributed to the market's reaction [2] - In the U.S. market, companies like BeiGene and Zai Lab saw their stocks drop over 9% following the news [2] - Other sectors, such as technology stocks, also faced declines, with notable drops in companies like Baidu and Alibaba, while gold stocks showed some activity with gains [3] Group 3 - Looking ahead, the outlook suggests that as the A-share market enters a valuation digestion phase, expectations of U.S. Federal Reserve easing may provide marginal support for Hong Kong stock valuations [4] - The Hong Kong internet sector is highlighted for its potential due to self-developed AI chips and cloud business expansion, which could enhance earnings certainty [4] - Overall, the low valuation of Hong Kong stocks, combined with improved asset quality and increased corporate dividends and buybacks, may attract foreign capital inflows [4]

Core Viewpoint - The Hong Kong stock market's innovative drug concept stocks are experiencing significant gains, with notable increases in share prices for several companies [1] Company Summaries - Heptagon Pharmaceuticals-B has surged nearly 10% [1] - CSPC Pharmaceutical Group and Innovent Biologics have both risen over 5% [1] - Zai Lab, Sinopharm Group, and China National Pharmaceutical Group are among the top gainers in this sector [1]